Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016

Abstract

After a period of major improvement, survival in SLE has plateaued since the mid-1990s. In high-income countries, 5-year survival exceeds 0.95 in both adults and children. In low/middle-income countries, 5-year and 10-year survival was lower among children than adults.

Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: A multicenter retrospective cohort study

“…The 5‐year and 10‐year survival rates were 96.9% and 95.5%, respectively, in our cohort with SLE, which are slightly higher than those reported in previous meta‐analyses but similar to those previously reported in Hong Kong (97% at 5 years and 93.7% at 10 years) and Shanghai (98% at 5 years) . However, because mortality in SLE varies according to not only the study populations’ characteristics, such as ethnicity and socioeconomic status, but also according to the study design and setting, it needs to be validated whether South Korean patients with SLE have a favorable outcome compared with those from other countries. Infection and active SLE are the leading causes for death in patients with SLE worldwide, and this notion is in line with our study's results.…”

“…A recent meta‐analysis demonstrated that 5‐year survival of patients with SLE in high‐income countries exceeded 95% in 2008‐2016, and the overall survival has reached a plateau since the mid‐1990s . The 5‐year and 10‐year survival rates were 96.9% and 95.5%, respectively, in our cohort with SLE, which are slightly higher than those reported in previous meta‐analyses but similar to those previously reported in Hong Kong (97% at 5 years and 93.7% at 10 years) and Shanghai (98% at 5 years) . However, because mortality in SLE varies according to not only the study populations’ characteristics, such as ethnicity and socioeconomic status, but also according to the study design and setting, it needs to be validated whether South Korean patients with SLE have a favorable outcome compared with those from other countries.…”

“…Survival of patents with SLE has considerably increased over the past few decades, with 5‐year and 10‐year survival rates increasing from 74.8% to 94.8% and from 63.2% to 91.4%, respectively, between the 1950s and the 2000s . A recent meta‐analysis demonstrated that 5‐year survival of patients with SLE in high‐income countries exceeded 95% in 2008‐2016, and the overall survival has reached a plateau since the mid‐1990s . The 5‐year and 10‐year survival rates were 96.9% and 95.5%, respectively, in our cohort with SLE, which are slightly higher than those reported in previous meta‐analyses but similar to those previously reported in Hong Kong (97% at 5 years and 93.7% at 10 years) and Shanghai (98% at 5 years) .…”

Monitoring Disease Activity in Systemic Lupus Erythematosus With Single‐Molecule Array Digital Enzyme‐Linked Immunosorbent Assay Quantification of Serum Interferon‐α

“…Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology characterized by the presence of antinuclear autoantibodies and inflammation in a wide spectrum of organs . The survival of SLE patients has plateaued since the middle 1990s . To date, anti–double‐stranded DNA (anti‐dsDNA) antibody titration, best achieved with the standard Farr assay, has been used to monitor global disease activity and SLE renal involvement .…”

Key genes and functional coexpression modules involved in the pathogenesis of systemic lupus erythematosus

“…2017; Paley, Strand, & Kim, 2017;Tektonidou, Lewandowski, Hu, Dasgupta, & Ward, 2017). Previous studies have identified that the etiology of SLE is multifactorial, and genetic predisposition and environmental factors both have critical roles in its pathogenesis (Moulton et al, 2017;Teruel & Alarcón-Riquelme, 2016;Tsokos, Lo, Reis, & Sullivan, 2016).…”